These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37916780)

  • 1. Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
    Frei K; Schecher S; Daher T; Hörner N; Richter J; Hildebrand U; Schindeldecker M; Witzel HR; Tsaur I; Porubsky S; Gaida MM; Roth W; Tagscherer KE
    Int J Cancer; 2024 Mar; 154(6):1082-1096. PubMed ID: 37916780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
    Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
    Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
    Wang C; Wang H; Lieftink C; du Chatinier A; Gao D; Jin G; Jin H; Beijersbergen RL; Qin W; Bernards R
    Gut; 2020 Apr; 69(4):727-736. PubMed ID: 31519701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
    Jiang B; Jiang J; Kaltheuner IH; Iniguez AB; Anand K; Ferguson FM; Ficarro SB; Seong BKA; Greifenberg AK; Dust S; Kwiatkowski NP; Marto JA; Stegmaier K; Zhang T; Geyer M; Gray NS
    Eur J Med Chem; 2021 Oct; 221():113481. PubMed ID: 33945934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
    Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
    Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
    Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
    Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
    Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
    Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
    Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
    Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
    Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
    J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
    Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma.
    Li Z; Li X; Seebacher NA; Liu X; Wu W; Yu S; Hornicek FJ; Huang C; Duan Z
    Carcinogenesis; 2024 Oct; 45(10):786-798. PubMed ID: 39082894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.
    Singh V; Jaiswal PK; Ghosh I; Koul HK; Yu X; De Benedetti A
    Int J Cancer; 2019 Aug; 145(4):1055-1067. PubMed ID: 30737777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer.
    Adams MN; Croft LV; Urquhart A; Saleem MAM; Rockstroh A; Duijf PHG; Thomas PB; Ferguson GP; Najib IM; Shah ET; Bolderson E; Nagaraj S; Williams ED; Nelson CC; O'Byrne KJ; Richard DJ
    Prostate; 2023 May; 83(7):628-640. PubMed ID: 36811381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
    Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
    Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
    Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Prostate Cancer, the 'Tousled Way'.
    Bhoir S; De Benedetti A
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.
    Zhong K; Luo W; Li N; Tan X; Li Y; Yin S; Huang Y; Fang L; Ma W; Cai Y; Yin Y
    Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38186306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.